An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|Clinical Microbiology and Infection|2021Cited by 107
Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced EmphysemaDirk‐Jan Slebos, J. Griffonet, Justin Garner et al.|CHEST Journal|2019Cited by 37
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trialFlorence Ader, Marion Noret, Nathan Peiffer‐Smadja et al.|medRxiv|2021Cited by 15
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trialDavid M. Smadja, France Mentré, Clément Massonnaud et al.|Scientific Reports|2025Cited by 7
The Prognosis of ART Is Not Altered in Cystic Fibrosis Women: A Case-Report StudyInès Braham, Nicolas Chevalier, Adeline Morisot et al.|Frontiers in Endocrinology|2022Cited by 3